Nan Zhang, Xiangying Xin, Deqiao Wu, Yan Zhang*, Hui Chen, Nannan Feng, Junwei Zhang, Yifan Zhu, Zhenzhong Zhang and Xia Xu
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China
*Corresponding Author: Yan Zhang, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Received: December 23, 2020; Published: January 16, 2021
Breast cancer is one of the most common malignant tumors among women worldwide. Since the 1970s, the incidence of breast cancer has always been the highest in women with tumors. Its incidence has shown an upward trend. Clinical medication for breast cancer has also been updated owing to social progress and development, particularly in the current mobile data networks. The mobile data network evolved from the 1G to the 5G era. Upon consulting literature, combined with the current understanding of the clinical application of breast cancer, the developmental changes and prospects of the clinical application of breast cancer in the 5G era were summarized. This review focused on the development of breast cancer from the 1G to 5G era. Beginning from the advent of the era of efficacy of the 1G era, represented by the introduction of paclitaxel and doxorubicin, to changes in docetaxel and epirubicin, with the arrival of the transitional era represented by chemical structure. With the advancement of science and technology, we entered the targeted era, represented by nano-preparations such as albumin paclitaxel and liposomal adriamycin. Currently, we are utilizing multi-drug combination therapy.
Keywords: Breast Cancer; Clinical Medication; 5G Era
Citation: Yan Zhang., et al. “Arrival of the 5G Era of Clinical Medicine for Breast Cancer”. Acta Scientific Pharmaceutical Sciences 5.2 (2021): 17-26.
Copyright: © 2021 Yan Zhang., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.